New psychoactive substances (NPS), psychedelic experiences, and dissociation: clinical and clinical pharmacological issues
Purpose of the review: A significant increase in the number, type, and availability of new psychoactive substances (NPS) with dissociative and psychedelic potential has occurred worldwide over the last few decades. Psychedelic substances have historically been used in order to achieve altered states of consciousness such as dissociative states. We aimed here at describing both the large number of novel ketamine-like dissociatives and tryptamine/lysergamide/phenethylamine psychedelics available, whilst describing the acute/long term clinical scenarios most commonly associated with their intake. Recent findings: An updated overview of the clinical and clinical pharmacological issues related to some of the most popular NPS categories has been provided, describing both psychosis and remaining psychopathological issues related to them. Conclusions: Although the complex link between NPS and psychiatric illnesses is yet to be fully understood, NPS misuse is now a significant clinical issue and an increasing challenge for clinicians working in both mental health and emergency departments.
Item Type | Article |
---|---|
Additional information | submitted 16 01 2019; revised version submitted 08 02 2019; accepted final 03 04 2019 |
Keywords | new psychoactive substances, nps, dissociation, psychedelics, drug-induced psychosis, drug misuse |
Date Deposited | 15 May 2025 14:03 |
Last Modified | 04 Jun 2025 17:10 |
-
picture_as_pdf - 03042019_final_accepted_paper_curr_add_reports_cs.pdf
-
subject - Submitted Version
- ['licenses_description_other' not defined]
- Available under ['licenses_typename_other' not defined]